A Phase 1b/2, Multi-Centered, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Microbiological Activity of a Single Dose of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa
Latest Information Update: 30 Apr 2025
At a glance
- Drugs Bacteriophage therapeutics-BiomX (Primary)
- Indications Bacterial infections; Cystic fibrosis; Pseudomonal infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms PHAGE
Most Recent Events
- 18 Apr 2025 Status changed from active, no longer recruiting to completed.
- 11 Apr 2025 Planned End Date changed from 18 Apr 2025 to 10 Apr 2025.
- 11 Apr 2025 Planned primary completion date changed from 18 Apr 2025 to 10 Apr 2025.